Ogivri savings card: as little as $0 per dose or prescription with commercial insurance

Ogivri is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Ogivri is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameOgivri

Authorized generictrastuzumab-dkst

Regular generictrastuzumab-dkst

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Ogivri?

The original

–

Brand nameThe maker’s card

My Biocon Biologics Co-Pay Card

Savings card from Biocon Biologics

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 per dose or prescription

Or call 1-833-695-2623.

In the maker’s words

“My Biocon Biologics Co-Pay Card patients may pay as little as: $0 out-of-pocket for each dose or prescription of the My Biocon Biologics product.”

From the maker’s offer on assets.bioconbiologics.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Ogivri itself, from the same company, sold without the brand name, and usually for less. For now Ogivri is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Ogivri is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Ogivri is a HER2/neu receptor antagonist indicated in adults for:

The treatment of HER2-overexpressing breast cancer.
The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Source: the FDA label for Ogivri (Biocon Biologics Inc.), June 26, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/ogivri/